BeiGene Ltd. (BGNE)
| Bid | 180.03 |
| Market Cap | 20.21B |
| Revenue (ttm) | 3.32B |
| Net Income (ttm) | -3.15B |
| EPS (ttm) | -8.19 |
| PE Ratio (ttm) | -22.553113553113555 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 189.93 |
| Volume | 329,397 |
| Avg. Volume (20D) | 357,765 |
| Open | 184.00 |
| Previous Close | 183.81 |
| Day's Range | 183.91 - 187.42 |
| 52-Week Range | 126.97 - 248.16 |
| Beta | 0.63 |
About BGNE
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tu...
Analyst Forecast
According to 6 analyst ratings, the average rating for BGNE stock is "Strong Buy." The 12-month stock price forecast is $288, which is an increase of 55.92% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
BeiGene to Announce First Quarter 2025 Financial Results on May 7SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will re...
2 months ago · seekingalpha.com
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with ...
